Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Douglas Smith

Showing results (21-30 of 203) with videos related to

Pageof 21
Sort By:
Journal of the National Cancer Institute|April 22, 2004
Cancer stem cells: are we missing the target?Richard J Jones, William H Matsui, B Douglas Smith
Blood|May 6, 2004
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effectsMark Levis, Rosalyn Pham, B Douglas Smith, et al.
Journal of Hospital Medicine|May 14, 2013
Myelodysplastic syndromes: what do hospitalists need to know?Amer M Zeidan, Bishoy Faltas, B Douglas Smith, et al.
Stem Cells (Dayton, Ohio)|April 22, 2011
Concise review: Emerging concepts in clinical targeting of cancer stem cellsZeshaan A Rasheed, Jeanne Kowalski, B Douglas Smith, et al.
Experimental Hematology|October 4, 2016
Translating leukemia stem cells into the clinical setting: Harmonizing the heterogeneityBreann Yanagisawa, Gabriel Ghiaur, B Douglas Smith, et al.
Blood|September 10, 2005
The paradox of response and survival in cancer therapeuticsCarol Ann Huff, William Matsui, B Douglas Smith, et al.
Leukemia & Lymphoma|July 12, 2013
Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapyB Douglas Smith, Dalia Mahmoud, Stacey Dacosta-Byfield, et al.
European Journal of Cancer (Oxford, England : 1990)|April 29, 2006
Strategies to eliminate cancer stem cells: clinical implicationsCarol Ann Huff, William H Matsui, B Douglas Smith, et al.
The American Journal of Medicine|March 20, 2013
Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS)Amer M Zeidan, B Douglas Smith, Rami S Komrokji, et al.
Leukemia Research|October 28, 2017
Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromesAmy E DeZern, Gary Binder, Quanhong Ni, et al.
Pageof 21

Showing results (21-30 of 203) with videos related to

Sort By:
Pageof 21
Journal of the National Cancer Institute|April 22, 2004
Cancer stem cells: are we missing the target?Richard J Jones, William H Matsui, B Douglas Smith
Blood|May 6, 2004
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effectsMark Levis, Rosalyn Pham, B Douglas Smith, et al.
Journal of Hospital Medicine|May 14, 2013
Myelodysplastic syndromes: what do hospitalists need to know?Amer M Zeidan, Bishoy Faltas, B Douglas Smith, et al.
Stem Cells (Dayton, Ohio)|April 22, 2011
Concise review: Emerging concepts in clinical targeting of cancer stem cellsZeshaan A Rasheed, Jeanne Kowalski, B Douglas Smith, et al.
Experimental Hematology|October 4, 2016
Translating leukemia stem cells into the clinical setting: Harmonizing the heterogeneityBreann Yanagisawa, Gabriel Ghiaur, B Douglas Smith, et al.
Blood|September 10, 2005
The paradox of response and survival in cancer therapeuticsCarol Ann Huff, William Matsui, B Douglas Smith, et al.
Leukemia & Lymphoma|July 12, 2013
Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapyB Douglas Smith, Dalia Mahmoud, Stacey Dacosta-Byfield, et al.
European Journal of Cancer (Oxford, England : 1990)|April 29, 2006
Strategies to eliminate cancer stem cells: clinical implicationsCarol Ann Huff, William H Matsui, B Douglas Smith, et al.
The American Journal of Medicine|March 20, 2013
Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS)Amer M Zeidan, B Douglas Smith, Rami S Komrokji, et al.
Leukemia Research|October 28, 2017
Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromesAmy E DeZern, Gary Binder, Quanhong Ni, et al.
Pageof 21